Idera Pharmaceuticals Announces the Granting of Patents on Immune Modulatory Compounds that Target Toll-like Receptors
July 17 2006 - 9:05AM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the
granting of patents in Europe (EU 1,278,761) and Australia (AU
2001257366) on immune modulatory oligonucleotides (IMO(TM)) that
target Toll-like Receptors (TLRs). The claims of these patents
cover both compositions of matter and methods of use for a broad
range of IMOs. The composition of matter claims include synthetic
immune stimulatory motifs, such as cytosine and 7-deazaguanosine,
and structural modifications to the oligonucleotides that affect
their immunological activity. Similar patents are pending in the
United States. "Idera has a portfolio of TLR9 agonists that are
DNA-based compounds containing unique synthetic immune stimulatory
motifs and other novel components. Use of our proprietary motifs
allows us to modulate immune responses to specifically address
various diseases", stated Sudhir Agrawal, D. Phil., Idera's Chief
Executive Officer and Chief Scientific Officer. "We believe that
the '761 and '366 patents provide protection for key
differentiating components of our TLR-targeted compounds." Idera
has approximately 150 patents and patent applications world-wide
covering agonists of TLR9, TLR8, and TLR7 and antagonists of TLR9.
Idera's entire portfolio of DNA and RNA-based compounds has been
designed through in-house structure-activity relationship studies.
The intent to grant EU 1,278,761 was published on April 6, 2005,
and the opposition period for this patent ended without opposition.
This patent has been validated in 20 European countries. About
Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug
discovery and development company with a pipeline of drug
candidates to treat cancer, and infectious, respiratory, and
autoimmune diseases. Idera's proprietary drug candidates are
designed to modulate TLRs, the body's first line of immune defense.
Idera's pioneering DNA chemistry expertise enables it to identify
drug candidates for internal development and creates opportunities
for multiple collaborative alliances. Idera's most advanced
clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonist candidates for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies will be
indicative of results that may be obtained in clinical trials;
whether the patents and patent applications owned or licensed by
Idera will protect the Company's technology and prevent others from
infringing it; whether Idera's cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera's Quarterly Report on Form 10-Q filed on May 12, 2006,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024